Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $28.8 million.

  • Journey Medical's Non-Current Assets rose 6107.82% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 5901.66%. This contributed to the annual value of $32.1 million for FY2024, which is 5721.29% up from last year.
  • Latest data reveals that Journey Medical reported Non-Current Assets of $28.8 million as of Q3 2025, which was up 6107.82% from $29.9 million recorded in Q2 2025.
  • Journey Medical's Non-Current Assets' 5-year high stood at $35.1 million during Q1 2023, with a 5-year trough of $12.8 million in Q4 2021.
  • For the 5-year period, Journey Medical's Non-Current Assets averaged around $25.2 million, with its median value being $27.5 million (2022).
  • As far as peak fluctuations go, Journey Medical's Non-Current Assets surged by 11484.64% in 2022, and later plummeted by 4433.15% in 2024.
  • Over the past 5 years, Journey Medical's Non-Current Assets (Quarter) stood at $12.8 million in 2021, then soared by 114.85% to $27.5 million in 2022, then fell by 25.79% to $20.4 million in 2023, then skyrocketed by 57.21% to $32.1 million in 2024, then dropped by 10.16% to $28.8 million in 2025.
  • Its Non-Current Assets stands at $28.8 million for Q3 2025, versus $29.9 million for Q2 2025 and $31.0 million for Q1 2025.